ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.65
0.48%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36775
0.00%
Bitcoin
68,691.11
-0.83%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ArQule Inc (ARQL)

  7. ArQule Inc (ARQL) News

ARQL

ArQule (ARQL)

ArQule Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARQL
DateTimeSourceHeadlineSymbolCompany
02/14/20204:35PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
02/14/202011:20AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARQLArQule Inc
02/12/20204:03PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
02/12/202011:05AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
02/10/202012:43PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
02/05/202010:29AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARQLArQule Inc
01/27/202012:55PMEdgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:ARQLArQule Inc
01/21/20205:00AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ARQLArQule Inc
01/21/20205:00AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ARQLArQule Inc
01/21/20205:00AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ARQLArQule Inc
01/06/202010:07AMPR Newswire (US)Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the FirmNASDAQ:ARQLArQule Inc
12/12/20192:49PMPR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.NASDAQ:ARQLArQule Inc
12/10/20192:02AMDow Jones NewsMerck, Sanofi Push To Add Cancer Drugs -- WSJNASDAQ:ARQLArQule Inc
12/09/20196:16PMDow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 4th UpdateNASDAQ:ARQLArQule Inc
12/09/20193:37PMDow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 3rd UpdateNASDAQ:ARQLArQule Inc
12/09/20192:12PMDow Jones NewsU.S. Stocks Slip as Trade War Weighs on Chinese ExportsNASDAQ:ARQLArQule Inc
12/09/20191:33PMDow Jones NewsBig Drugmakers Push Deeper Into Cancer Treatment -- 2nd UpdateNASDAQ:ARQLArQule Inc
12/09/201910:13AMDow Jones NewsMerck to Buy ArQule for $2.7 Billion -- UpdateNASDAQ:ARQLArQule Inc
12/09/20197:05AMBusiness WireArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology...NASDAQ:ARQLArQule Inc
12/09/20196:37AMPR Newswire (US)(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price?NASDAQ:ARQLArQule Inc
12/09/20196:26AMDow Jones NewsMerck to Buy ArQule for $2.7 Billion, or $20/ShareNASDAQ:ARQLArQule Inc
12/09/20195:45AMBusiness WireMerck to Acquire ArQule, Advancing Leadership in OncologyNASDAQ:ARQLArQule Inc
11/25/20196:00AMBusiness WireArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual ...NASDAQ:ARQLArQule Inc
11/13/20196:00AMBusiness WireArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019NASDAQ:ARQLArQule Inc
11/06/20198:05AMBusiness WireArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversi...NASDAQ:ARQLArQule Inc
10/30/20199:57AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ARQLArQule Inc
10/30/20196:30AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARQLArQule Inc
10/30/20196:00AMBusiness WireArQule Reports Third Quarter 2019 Financial ResultsNASDAQ:ARQLArQule Inc
10/29/20193:01PMBusiness WireArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Ther...NASDAQ:ARQLArQule Inc
10/21/20196:00AMBusiness WireArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformati...NASDAQ:ARQLArQule Inc
 Showing the most relevant articles for your search:NASDAQ:ARQL

Your Recent History

GATE
PETUSDT
Pet Token
LSE
BAY
Bay Capital
LSE
3LVE
Granite 3l Nvda
TSXV
MMA
Midnight Sun Mining
NASDAQ
FOSL
Fossil
HITB
ACSUSDT
Access Protocol
COIN
PPTKGBP
BIT
UB4QAW
Unicredit Bank
NYSE
CXM
Sprinklr
BIT
UB6JLG
Unicredit Bank
NASDAQ
FMZKQX
Innovative Technology Po...
ASX
CDUR
HITB
REIBTC
REI Network
BIT
UB2Y6L
UniCredit Bank
ASX
VXRNA
EU
IEXS1
ISHARES EXS1 INAV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved